<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597217</url>
  </required_header>
  <id_info>
    <org_study_id>C1171013</org_study_id>
    <nct_id>NCT03597217</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults</brief_title>
  <official_title>A Phase 1, 2-part Study Of Pf-05221304 In Healthy Japanese Adults: Part 1 - Randomized, Double-blind, Crossover, Single Dose Assessment Of Pharmacokinetics And Safety; Part 2- Randomized, Double-blind, Placebo-controlled, Multiple Dose Assessment Of Safety, Tolerability And Pharmacokinetics Of Pf-05221304</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to evaluate the safety, tolerability and pharmacokinetics of
      PF-05221304 in healthy Japanese adult subjects following single and multiple dose
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">November 15, 2018</completion_date>
  <primary_completion_date type="Actual">November 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A: Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Time to reach Cmax (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Area under the plasma concentration time profile from time zero extrapolated to infinite time (as data permit) (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Terminal half life (as data permit) (t1/2)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Apparent clearance (as data permit) (CL/F)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort A: Apparent volume of distribution (as data permit) (Vz/F)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort B: Number of Subjects experiencing an Adverse Event</measure>
    <time_frame>Screening up to 28 days after last dose of study medication</time_frame>
    <description>Assessment of adverse events (AEs), clinical laboratory tests, vital signs (including blood pressure and pulse rate) and 12 lead ECG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort A: Number of Subjects experiencing an Adverse Event</measure>
    <time_frame>Screening up to 28 days after last dose of study medication</time_frame>
    <description>Assessment of adverse events (AEs), clinical laboratory tests, vital signs (including blood pressure and pulse rate) and 12 lead ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Area under the plasma concentration time profile from time zero to time τ (tau), the dosing interval (ACUtau)(Day 1)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Area under the plasma concentration time profile from time zero to time τ (tau), the dosing interval (ACUtau)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Maximum plasma concentration during the dosing interval (Cmax)(Day 1)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Maximum plasma concentration during the dosing interval (Cmax)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Time to reach Cmax (Tmax)(Day 1)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Time to reach Cmax (Tmax)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Minimum plasma concentration during the dosing interval (Cmin)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Peak trough ratio (PTR)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Observed accumulation ratio (Rac)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Observed accumulation ratio for Cmax (Rac,Cmax)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Terminal half life (t1/2)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Apparent volume of distribution (Vz/F)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort B: Apparent clearance (CL/F)(Day 14)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 single doses treatment of PF-05221304</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated doses of PF-05221304</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeated doses of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304</intervention_name>
    <description>3, 10, 50 mg</description>
    <arm_group_label>Cohort A_Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304</intervention_name>
    <description>50 mg multiple dose</description>
    <arm_group_label>Cohort B_Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort B_Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects who, at the time of screening, are between the ages of
             20 and 55 years, inclusive.

          -  Body mass index (BMI) of 17.5-30.5 kg/m2 inclusive; and a total body weight &gt;50 kg
             (110 lb).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing) or clinical findings at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P-one Clinic, Keikokai Medical Corporation</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1171013&amp;StudyName=A+Phase+1%2C+2-part+Study+Of+Pf-05221304+In+Healthy+Japanese+Adults%3A+Part+1+-+Randomized%2C+Double-blind%2C+Crossover%2C+Single+Dose+Assessment+Of+Pharmacokinetics+And+Safety%3B+Part+2-+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multiple+Dose+Assessment+Of+Safety%2C+Tolerability+And+Pharmacokinetics+Of+Pf-05221034</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1171013&amp;StudyName=A+Phase+1%2C+2-part+Study+Of+Pf-05221304+In+Healthy+Japanese+Adults%3A+Part+1+-+Randomized%2C+Double-blind%2C+Crossover%2C+Single+Dose+Assessment+Of+Pharmacokinetics+And+Safety%3B+Part+2-+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multiple+Dose+Assessment+Of+Safety%2C+Tolerability+And+Pharmacokinetics+Of+Pf-05221304</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-05221304, PK, Japanese, NASH, ACC inhibitor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

